Borregaard（0QB7）株式概要Borregaard ASAは、ノルウェー、その他のヨーロッパ諸国、アジア、米国、および国際的に、特殊なバイオケミカルおよびバイオマテリアルの開発、生産、マーケティングに従事している。 詳細0QB7 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長4/6過去の実績1/6財務の健全性6/6配当金4/6報酬当社が推定した公正価値より48.2%で取引されている 収益は年間54.66%増加すると予測されています リスク分析2.98%の配当は利益で十分にカバーされていない 利益率(2.2%)は昨年より低い(11.4%) すべてのリスクチェックを見る0QB7 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW466,456 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA466,456 investors already sharing narrativesYour Fair ValueNOK Current PriceNOK 159.1214.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture010b2016201920222025202620282031Revenue NOK 9.6bEarnings NOK 208.8mAdvancedSet Fair ValueView all narrativesBorregaard ASA 競合他社ElementisSymbol: LSE:ELMMarket cap: UK£1.0bCroda InternationalSymbol: LSE:CRDAMarket cap: UK£4.8bIofinaSymbol: AIM:IOFMarket cap: UK£95.9mHardideSymbol: AIM:HDDMarket cap: UK£76.8m価格と性能株価の高値、安値、推移の概要Borregaard過去の株価現在の株価NOK 159.1252週高値NOK 211.5052週安値NOK 138.00ベータ0.571ヶ月の変化0.10%3ヶ月変化7.04%1年変化-23.87%3年間の変化3.73%5年間の変化-28.32%IPOからの変化659.53%最新ニュースReported Earnings • Jul 19Second quarter 2026 earnings released: kr1.27 loss per share (vs kr2.56 profit in 2Q 2025)Second quarter 2026 results: kr1.27 loss per share (down from kr2.56 profit in 2Q 2025). Revenue: kr2.11b (up 3.4% from 2Q 2025). Net loss: kr127.0m (down 150% from profit in 2Q 2025). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 12% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.New Risk • May 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.2% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.Reported Earnings • May 02First quarter 2026 earnings released: EPS: kr1.82 (vs kr2.52 in 1Q 2025)First quarter 2026 results: EPS: kr1.82 (down from kr2.52 in 1Q 2025). Revenue: kr2.01b (down 1.5% from 1Q 2025). Net income: kr182.0m (down 28% from 1Q 2025). Profit margin: 9.1% (down from 12% in 1Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.Upcoming Dividend • Apr 10Upcoming dividend of kr4.75 per shareEligible shareholders must have bought the stock before 17 April 2026. Payment date: 27 April 2026. Payout ratio and cash payout ratio are on the higher end at 76% and 84% respectively. Trailing yield: 2.7%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (3.9%).Declared Dividend • Feb 06Dividend increased to kr4.75Dividend of kr4.75 is 12% higher than last year. Ex-date: 17th April 2026 Payment date: 27th April 2026 Dividend yield will be 2.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (76% earnings payout ratio) and cash flows (84% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 05Full year 2025 earnings released: EPS: kr6.22 (vs kr8.26 in FY 2024)Full year 2025 results: EPS: kr6.22 (down from kr8.26 in FY 2024). Revenue: kr7.71b (up 1.3% from FY 2024). Net income: kr620.0m (down 25% from FY 2024). Profit margin: 8.0% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.最新情報をもっと見るRecent updatesReported Earnings • Jul 19Second quarter 2026 earnings released: kr1.27 loss per share (vs kr2.56 profit in 2Q 2025)Second quarter 2026 results: kr1.27 loss per share (down from kr2.56 profit in 2Q 2025). Revenue: kr2.11b (up 3.4% from 2Q 2025). Net loss: kr127.0m (down 150% from profit in 2Q 2025). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 12% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.New Risk • May 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.2% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.Reported Earnings • May 02First quarter 2026 earnings released: EPS: kr1.82 (vs kr2.52 in 1Q 2025)First quarter 2026 results: EPS: kr1.82 (down from kr2.52 in 1Q 2025). Revenue: kr2.01b (down 1.5% from 1Q 2025). Net income: kr182.0m (down 28% from 1Q 2025). Profit margin: 9.1% (down from 12% in 1Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.Upcoming Dividend • Apr 10Upcoming dividend of kr4.75 per shareEligible shareholders must have bought the stock before 17 April 2026. Payment date: 27 April 2026. Payout ratio and cash payout ratio are on the higher end at 76% and 84% respectively. Trailing yield: 2.7%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (3.9%).Declared Dividend • Feb 06Dividend increased to kr4.75Dividend of kr4.75 is 12% higher than last year. Ex-date: 17th April 2026 Payment date: 27th April 2026 Dividend yield will be 2.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (76% earnings payout ratio) and cash flows (84% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 05Full year 2025 earnings released: EPS: kr6.22 (vs kr8.26 in FY 2024)Full year 2025 results: EPS: kr6.22 (down from kr8.26 in FY 2024). Revenue: kr7.71b (up 1.3% from FY 2024). Net income: kr620.0m (down 25% from FY 2024). Profit margin: 8.0% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Feb 04Borregaard ASA Proposes Ordinary Dividend for 2025, Payable on 27 April 2026The Board of Directors of Borregaard ASA at a meeting on 3 February 2026 decided to propose an ordinary dividend for 2025 of NOK 4.75 per share to the Annual General Meeting. Dividend payment is estimated at NOK 474 million. The exact amount will depend on the number of treasury shares held at the date of the Annual General Meeting. No dividend will be paid on treasury shares held by the Borregaard Group. Provided that the traded shares are subject to ordinary settlement in the Norwegian Securities Register (VPS), shares acquired up to and including 16 April 2026 will carry the right to receive dividends, whereas shares that are acquired on and after 17 April 2026 will not carry the right to receive dividends. Subject to the decision of the Annual General Meeting, the dividend will be paid on 27 April 2026 to shareholders registered in the company’s shareholders’ register as evidenced in a transcript as of 20 April 2026. The share will be quoted ex dividend on 17 April 2026. The Annual General Meeting of Borregaard ASA will be held on Thursday 16 April 2026 at 1 p.m. (13:00 CEST) in Sarpsborg as a digital meeting.Board Change • Dec 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director John Ulvan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Sep 27Borregaard Announces NOK 15 Million Award for Biomer Project to Develop Bio-Based Alternatives to PolycarboxylatesThe Norwegian Research Council has awarded NOK 15 million to support Borregaard’s innovation initiative, Biomer. The project aims to develop bio-based alternatives to polycarboxylates – fossil-based polymers commonly used in agriculture, industry, and household products. Polycarboxylates are known for their persistence in the environment and high carbon footprint. Through Biomer, Borregaard will develop new ways to turn Norwegian bioresources into greener polymers designed to replace these fossil-based materials. The project will leverage Borregaard’s advanced biorefinery in Sarpsborg and its expertise in wood chemistry to deliver sustainable solutions with significantly lower environmental impact.お知らせ • Aug 25+ 5 more updatesBorregaard ASA to Report Q1, 2026 Results on Apr 29, 2026Borregaard ASA announced that they will report Q1, 2026 results on Apr 29, 2026New Risk • Jul 17New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 41% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Dividend is not well covered by cash flows (91% cash payout ratio).Reported Earnings • Jul 17Second quarter 2025 earnings released: EPS: kr2.56 (vs kr2.45 in 2Q 2024)Second quarter 2025 results: EPS: kr2.56 (up from kr2.45 in 2Q 2024). Revenue: kr2.05b (up 4.9% from 2Q 2024). Net income: kr255.0m (up 4.5% from 2Q 2024). Profit margin: 13% (in line with 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 5% per year.Buy Or Sell Opportunity • Jul 16Now 23% undervaluedOver the last 90 days, the stock has risen 20% to kr197. The fair value is estimated to be kr255, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years, while earnings per share has been flat.お知らせ • Jun 21+ 1 more updateBorregaard ASA Announces Earnings Guidance for the Second Quarter of 2025 and the Full Year 2025Borregaard ASA announced earnings guidance for the second quarter and the full year 2025. For the second quarter, the sales volume is expected to be approximately 85,000 tonnes, which is seasonally higher than in the first quarter. The company expects a less favorable product mix as they normally have lower sales and lower share of specialties. Still, the sales will be driven by strong sales through agriculture also . For the full year 2025,the sales volume is expected to be approximately 330,000 tonnes, driven by strong sales through agriculture. This also implies a positive mix effect.お知らせ • Jun 13Borregaard ASA Announces Change in Group Executive Management, Effective August 1, 2025Knut-Harald Bakke has been appointed EVP BioSolutions, effective 1 August 2025. He will also join the Group Executive Management on the same date. Bakke succeeds Tom Erik Foss-Jacobsen, who will assume the role of CEO on 1 August. Bakke currently serves as Director of Investor Relations and has previously held the position of Energy Director at Borregaard. Prior to joining the company in 2019, he held senior leadership roles at Norsk Hydro, where he was responsible for global energy market operations. He holds an MSc in Industrial Economics and Technology Management from the Norwegian University of Science and Technology (NTNU). Borregaard will initiate a process to appoint a new Director of Investor Relations. In the interim, CFO Per Bjarne Lyngstad will assume the responsibility from 1 August.Recent Insider Transactions • Jun 02Independent Director recently bought kr376k worth of stockOn the 27th of May, John Ulvan bought around 2k shares on-market at roughly kr188 per share. This transaction amounted to 57% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr752k more in shares than they have sold in the last 12 months.Recent Insider Transactions • May 30Independent Director recently bought kr376k worth of stockOn the 27th of May, John Ulvan bought around 2k shares on-market at roughly kr188 per share. This transaction amounted to 57% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr752k more in shares than they have sold in the last 12 months.Reported Earnings • May 02First quarter 2025 earnings released: EPS: kr2.52 (vs kr2.01 in 1Q 2024)First quarter 2025 results: EPS: kr2.52 (up from kr2.01 in 1Q 2024). Revenue: kr2.04b (up 3.1% from 1Q 2024). Net income: kr251.0m (up 26% from 1Q 2024). Profit margin: 12% (up from 10% in 1Q 2024). Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 1% per year.Upcoming Dividend • Apr 04Upcoming dividend of kr4.25 per shareEligible shareholders must have bought the stock before 11 April 2025. Payment date: 23 April 2025. Payout ratio is a comfortable 51% but the company is paying out more than the cash it is generating. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (6.2%). Lower than average of industry peers (4.7%).Reported Earnings • Mar 23Full year 2024 earnings released: EPS: kr8.26 (vs kr8.73 in FY 2023)Full year 2024 results: EPS: kr8.26 (down from kr8.73 in FY 2023). Revenue: kr7.62b (up 6.8% from FY 2023). Net income: kr823.0m (down 5.4% from FY 2023). Profit margin: 11% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year.Declared Dividend • Jan 31Dividend increased to kr4.25Dividend of kr4.25 is 13% higher than last year. Ex-date: 11th April 2025 Payment date: 23rd April 2025 Dividend yield will be 2.1%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (52% earnings payout ratio) but not covered by cash flows (119% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Jan 30Full year 2024 earnings released: EPS: kr8.25 (vs kr8.73 in FY 2023)Full year 2024 results: EPS: kr8.25 (down from kr8.73 in FY 2023). Revenue: kr7.62b (up 6.8% from FY 2023). Net income: kr823.0m (down 5.4% from FY 2023). Profit margin: 11% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year.お知らせ • Jan 29Borregaard Asa Proposes Ordinary Dividend for 2024, Payable on 23 April 2025At a meeting on 30 January 2024, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary dividend for 2024 of NOK 4.25 per share. Ex-date: 11 April 2025. Record date: 14 April 2025. Payment date: 23 April 2025. Date of approval: 10 April 2025.Reported Earnings • Nov 01Third quarter 2024 earnings released: EPS: kr2.51 (vs kr2.38 in 3Q 2023)Third quarter 2024 results: EPS: kr2.51 (up from kr2.38 in 3Q 2023). Revenue: kr1.95b (up 14% from 3Q 2023). Net income: kr250.0m (up 5.5% from 3Q 2023). Profit margin: 13% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.お知らせ • Sep 20Borregaard ASA, Annual General Meeting, Apr 10, 2025Borregaard ASA, Annual General Meeting, Apr 10, 2025.お知らせ • Sep 19+ 3 more updatesBorregaard ASA to Report Q3, 2025 Results on Oct 22, 2025Borregaard ASA announced that they will report Q3, 2025 results on Oct 22, 2025Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr2.45 (vs kr2.84 in 2Q 2023)Second quarter 2024 results: EPS: kr2.45 (down from kr2.84 in 2Q 2023). Revenue: kr1.95b (flat on 2Q 2023). Net income: kr244.0m (down 14% from 2Q 2023). Profit margin: 13% (down from 14% in 2Q 2023). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 6.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director John Ulvan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: kr2.01 (vs kr2.32 in 1Q 2023)First quarter 2024 results: EPS: kr2.01 (down from kr2.32 in 1Q 2023). Revenue: kr1.98b (up 6.8% from 1Q 2023). Net income: kr200.0m (down 13% from 1Q 2023). Profit margin: 10% (down from 13% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Apr 05Upcoming dividend of kr3.75 per shareEligible shareholders must have bought the stock before 12 April 2024. Payment date: 22 April 2024. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (2.9%).Reported Earnings • Mar 22Full year 2023 earnings released: EPS: kr8.73 (vs kr8.95 in FY 2022)Full year 2023 results: EPS: kr8.73 (down from kr8.95 in FY 2022). Revenue: kr7.13b (up 3.6% from FY 2022). Net income: kr870.0m (down 2.5% from FY 2022). Profit margin: 12% (in line with FY 2022). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 3.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Feb 07Now 21% undervaluedOver the last 90 days, the stock has risen 9.3% to kr176. The fair value is estimated to be kr224, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 21%. For the next 3 years, revenue is forecast to grow by 3.1% per annum. Earnings are also forecast to grow by 9.2% per annum over the same time period.Declared Dividend • Feb 02Dividend increased to kr3.75Dividend of kr3.75 is 15% higher than last year. Ex-date: 12th April 2024 Payment date: 22nd April 2024 Dividend yield will be 2.0%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (43% earnings payout ratio) and cash flows (42% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 01Full year 2023 earnings released: EPS: kr8.73 (vs kr8.95 in FY 2022)Full year 2023 results: EPS: kr8.73 (down from kr8.95 in FY 2022). Revenue: kr7.13b (up 3.6% from FY 2022). Net income: kr870.0m (down 2.5% from FY 2022). Profit margin: 12% (in line with FY 2022). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 4.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 31Borregaard ASA Proposes Cash Dividend for 2023, Payable on 22 April 2024At a meeting on 30 January 2024, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary dividend for 2023 of NOK 3.75 per share. Ex-date: 12 April 2024. Record date: 15 April 2024. Payment date: 22 April 2024. Date of approval: 11 April 2024.お知らせ • Nov 29Borregaard ASA (OB:BRG) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved from April 18, 2023.Borregaard ASA (OB:BRG) commences share repurchases on November 20, 2023, under the program mandated by the shareholders in the Annual General Meeting held on April 18, 2023. As per the mandate, the company is authorized to repurchase up to a total nominal value of NOK 10 million, corresponding to 10% of the share capital. The shares will be repurchased at a price not more than NOK 400 per share and no less than NOK 1 per share. The company may repurchase and dispose of its own shares to fulfil its incentive schemes. The repurchases will be used for amortization. The plan will be valid up to the 2024 Annual General Meeting, but no later than June 30, 2024. On November 17, 2023, the company announced its intention of repurchasing 200,000 shares of its outstanding common stock. The repurchase of shares will be conducted in a period from November 20, 2023, up to and including December 20, 2023 at the latest.Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: kr2.38 (vs kr2.40 in 3Q 2022)Third quarter 2023 results: EPS: kr2.38 (down from kr2.40 in 3Q 2022). Revenue: kr1.71b (down 2.2% from 3Q 2022). Net income: kr237.0m (flat on 3Q 2022). Profit margin: 14% (in line with 3Q 2022). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 6.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 25+ 5 more updatesBorregaard ASA, Annual General Meeting, Apr 11, 2024Borregaard ASA, Annual General Meeting, Apr 11, 2024, at 13:00 Central European Standard Time.New Risk • Jul 19New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 43% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company.Reported Earnings • Jul 19Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr1.96b (up 13% from 2Q 2022). Net income: kr283.0m (up 12% from 2Q 2022). Profit margin: 14% (in line with 2Q 2022). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 7.5% decline forecast for the Chemicals industry in the United Kingdom.Buying Opportunity • Jun 12Now 20% undervaluedOver the last 90 days, the stock is up 7.5%. The fair value is estimated to be kr229, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 11% in 2 years. Earnings is forecast to grow by 6.5% in the next 2 years.Buying Opportunity • May 26Now 20% undervaluedOver the last 90 days, the stock is up 3.4%. The fair value is estimated to be kr231, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 11% in 2 years. Earnings is forecast to grow by 6.5% in the next 2 years.Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr2.32 (vs kr2.18 in 1Q 2022)First quarter 2023 results: EPS: kr2.32 (up from kr2.18 in 1Q 2022). Revenue: kr1.85b (up 15% from 1Q 2022). Net income: kr231.0m (up 6.5% from 1Q 2022). Profit margin: 13% (in line with 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Apr 12Upcoming dividend of kr3.25 per share at 1.9% yieldEligible shareholders must have bought the stock before 19 April 2023. Payment date: 27 April 2023. Payout ratio is a comfortable 36% but the company is paying out more than the cash it is generating. Trailing yield: 1.9%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (2.4%).Reported Earnings • Feb 05Full year 2022 earnings released: EPS: kr8.95 (vs kr6.95 in FY 2021)Full year 2022 results: EPS: kr8.95 (up from kr6.95 in FY 2021). Revenue: kr6.88b (up 19% from FY 2021). Net income: kr892.0m (up 29% from FY 2021). Profit margin: 13% (up from 12% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 1.6% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to kr179, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 96% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr78.03 per share.お知らせ • Feb 02Borregaard ASA Proposes Ordinary Dividend for 2022, Payable on 27 April 2023At a meeting on 1 February 2023, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary dividend for 2022 of NOK 3.25 per share. Ex-date: 19 April 2023; Record date: 20 April 2023; Payment date: 27 April 2023; Date of approval: 18 April 2023.Recent Insider Transactions • Dec 11Independent Chairman recently bought kr95k worth of stockOn the 9th of December, Helge Aasen bought around 600 shares on-market at roughly kr159 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr217k. This was Helge's only on-market trade for the last 12 months.Recent Insider Transactions • Dec 11Independent Chairman recently bought kr95k worth of stockOn the 9th of December, Helge Aasen bought around 600 shares on-market at roughly kr159 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr217k. This was Helge's only on-market trade for the last 12 months.Recent Insider Transactions • Nov 03Director recently bought kr217k worth of stockOn the 1st of November, John Ulvan bought around 2k shares on-market at roughly kr145 per share. This transaction amounted to 75% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.5m more in shares than they have sold in the last 12 months.Buying Opportunity • Nov 02Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 20%. The fair value is estimated to be kr179, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 29%. For the next 3 years, revenue is forecast to grow by 1.4% per annum. Earnings is forecast to decline by 1.6% per annum over the same time period.Reported Earnings • Oct 21Third quarter 2022 earnings released: EPS: kr2.40 (vs kr2.12 in 3Q 2021)Third quarter 2022 results: EPS: kr2.40 (up from kr2.12 in 3Q 2021). Revenue: kr1.75b (up 23% from 3Q 2021). Net income: kr239.0m (up 13% from 3Q 2021). Profit margin: 14% (down from 15% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.4% p.a. on average during the next 3 years, compared to a 8.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 27+ 4 more updatesBorregaard ASA to Report Q4, 2022 Results on Feb 02, 2023Borregaard ASA announced that they will report Q4, 2022 results at 7:00 AM, Central European Standard Time on Feb 02, 2023Reported Earnings • Jul 16Second quarter 2022 earnings released: EPS: kr2.52 (vs kr2.34 in 2Q 2021)Second quarter 2022 results: EPS: kr2.52 (up from kr2.34 in 2Q 2021). Revenue: kr1.74b (up 15% from 2Q 2021). Net income: kr252.0m (up 8.2% from 2Q 2021). Profit margin: 14% (down from 15% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12% compared to a 16% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • May 14Insider recently bought kr709k worth of stockOn the 12th of May, Gisle Johansen bought around 11k shares on-market at roughly kr65.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr2.3m more in shares than they have sold in the last 12 months.Reported Earnings • May 03First quarter 2022 earnings released: EPS: kr2.18 (vs kr1.46 in 1Q 2021)First quarter 2022 results: EPS: kr2.18 (up from kr1.46 in 1Q 2021). Revenue: kr1.62b (up 14% from 1Q 2021). Net income: kr217.0m (up 49% from 1Q 2021). Profit margin: 13% (up from 10% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to stay flat compared to a 16% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 26% per year.Upcoming Dividend • Apr 01Upcoming dividend of kr5.00 per shareEligible shareholders must have bought the stock before 08 April 2022. Payment date: 21 April 2022. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (4.7%). Lower than average of industry peers (2.6%).Reported Earnings • Mar 19Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: kr5.81b (up 9.0% from FY 2020). Net income: kr692.0m (up 59% from FY 2020). Profit margin: 12% (up from 8.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 3.1% compared to a 11% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Feb 04Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: kr6.95 (up from kr4.37 in FY 2020). Revenue: kr5.81b (up 9.0% from FY 2020). Net income: kr692.0m (up 59% from FY 2020). Profit margin: 12% (up from 8.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 8.5% compared to a 3.3% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Dec 07Insider recently bought kr710k worth of stockOn the 6th of December, Kristin Misund bought around 10k shares on-market at roughly kr70.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr3.0m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Nov 27General Counsel recently sold kr268k worth of stockOn the 25th of November, Rolf Heggen sold around 1k shares on-market at roughly kr223 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr2.3m more than they sold in the last 12 months.Recent Insider Transactions • Oct 28Independent Director recently bought kr424k worth of stockOn the 27th of October, Tove Andersen bought around 2k shares on-market at roughly kr212 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.4m. Insiders have collectively bought kr2.5m more in shares than they have sold in the last 12 months.Reported Earnings • Oct 22Third quarter 2021 earnings released: EPS kr2.12 (vs kr1.12 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr1.43b (up 13% from 3Q 2020). Net income: kr211.0m (up 88% from 3Q 2020). Profit margin: 15% (up from 8.9% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Jul 30General Counsel recently bought kr1.4m worth of stockOn the 29th of July, Rolf Heggen bought around 15k shares on-market at roughly kr91.56 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr461k more in shares than they have sold in the last 12 months.Reported Earnings • Jul 17Second quarter 2021 earnings released: EPS kr2.34The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr1.51b (up 11% from 2Q 2020). Net income: kr233.0m (up 131% from 2Q 2020). Profit margin: 15% (up from 7.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.Reported Earnings • Apr 29First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr1.42b (up 3.4% from 1Q 2020). Net income: kr146.0m (up 43% from 1Q 2020). Profit margin: 10% (up from 7.4% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.Executive Departure • Apr 20Independent Chairman Jan Oksum has left the companyOn the 14th of April, Jan Oksum's tenure in the role of Independent Chairman ended. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months.Upcoming Dividend • Apr 08Upcoming dividend of kr2.50 per shareEligible shareholders must have bought the stock before 15 April 2021. Payment date: 23 April 2021. Trailing yield: 1.3%. Lower than top quartile of British dividend payers (4.3%). Lower than average of industry peers (1.7%).Reported Earnings • Mar 26Full year 2020 earnings released: EPS kr4.37 (vs kr4.18 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr5.33b (up 5.2% from FY 2019). Net income: kr436.0m (up 4.6% from FY 2019). Profit margin: 8.2% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.Recent Insider Transactions • Mar 20Insider recently bought kr1.4m worth of stockOn the 18th of March, Gisle Johansen bought around 15k shares on-market at roughly kr94.06 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr205k more in shares than they bought in the last 12 months.Is New 90 Day High Low • Feb 20New 90-day high: kr168The company is up 27% from its price of kr132 on 20 November 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr169 per share.Reported Earnings • Feb 05Full year 2020 earnings released: EPS kr4.36 (vs kr4.17 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr5.33b (up 5.2% from FY 2019). Net income: kr436.0m (up 4.6% from FY 2019). Profit margin: 8.2% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 05Revenue beats expectationsRevenue exceeded analyst estimates by 2.2%. Over the next year, revenue is expected to shrink by 1.2% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.Is New 90 Day High Low • Feb 05New 90-day high: kr167The company is up 22% from its price of kr137 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr162 per share.Is New 90 Day High Low • Jan 05New 90-day high: kr145The company is up 2.0% from its price of kr142 on 07 October 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr165 per share.Analyst Estimate Surprise Post Earnings • Oct 22Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 0.3% at kr1.26b. Revenue is forecast to grow 2.3% over the next year, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.Reported Earnings • Oct 22Third quarter earnings releasedOver the last 12 months the company has reported total profits of kr353.0m, down 23% from the prior year. Total revenue was kr5.22b over the last 12 months, up 3.5% from the prior year.Recent Insider Transactions • Sep 18Board Observer recently sold kr67k worth of stockOn the 15th of September, Bente Klausen sold around 500 shares on-market at roughly kr133 per share. In the last 3 months, there was an even bigger sale from another insider worth kr1.3m. Insiders have been net sellers, collectively disposing of kr919k more than they bought in the last 12 months.株主還元0QB7GB ChemicalsGB 市場7D0.2%-4.9%0.7%1Y-23.9%13.6%16.3%株主還元を見る業界別リターン: 0QB7過去 1 年間で13.6 % の収益を上げたUK Chemicals業界を下回りました。リターン対市場: 0QB7は、過去 1 年間で16.3 % のリターンを上げたUK市場を下回りました。価格変動Is 0QB7's price volatile compared to industry and market?0QB7 volatility0QB7 Average Weekly Movement3.4%Chemicals Industry Average Movement6.4%Market Average Movement5.0%10% most volatile stocks in GB Market10.4%10% least volatile stocks in GB Market2.6%安定した株価: 0QB7 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 0QB7の 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20121,193Tom Foss-Jacobsenwww.borregaard.comBorregaard ASAは、ノルウェー、その他のヨーロッパ諸国、アジア、米国、および国際的に、特殊な生化学物質およびバイオマテリアルの開発、生産、マーケティングに従事している。事業セグメントは3つ：バイオソリューション事業、バイオマテリアル事業、ファインケミカル事業である。バイオソリューション事業では、リグニン由来のバイオポリマーやバイオバニリンを、農薬、電池、工業用バインダー、建築、香料会社、食品・飲料業界向けに開発、製造、販売している。バイオマテリアル事業では、セルロースエーテル、セルロースアセテート、その他の特殊製品の原料として使用される特殊セルロースや、工業用途のセルロースフィブリルを開発、製造、販売している。ファインケミカル事業では、造影剤や先端バイオエタノール用のファインケミカル中間体を供給している。同社は2012年に設立され、ノルウェーのサルプスボルグに本社を置いている。もっと見るBorregaard ASA 基礎のまとめBorregaard の収益と売上を時価総額と比較するとどうか。0QB7 基礎統計学時価総額NOK 15.90b収益（TTM）NOK 169.00m売上高(TTM)NOK 7.75b94.1xPER（株価収益率2.1xP/Sレシオ0QB7 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0QB7 損益計算書（TTM）収益NOK 7.75b売上原価NOK 2.79b売上総利益NOK 4.96bその他の費用NOK 4.80b収益NOK 169.00m直近の収益報告Jun 30, 2026次回決算日Oct 28, 2026一株当たり利益（EPS）1.70グロス・マージン64.04%純利益率2.18%有利子負債／自己資本比率32.4%0QB7 の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.0%現在の配当利回り281%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/23 07:51終値2026/08/21 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Borregaard ASA 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関null nullABG Sundal CollierSebastian BrayBerenbergAndres Castanos-MollorBerenberg3 その他のアナリストを表示
Reported Earnings • Jul 19Second quarter 2026 earnings released: kr1.27 loss per share (vs kr2.56 profit in 2Q 2025)Second quarter 2026 results: kr1.27 loss per share (down from kr2.56 profit in 2Q 2025). Revenue: kr2.11b (up 3.4% from 2Q 2025). Net loss: kr127.0m (down 150% from profit in 2Q 2025). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 12% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
New Risk • May 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.2% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
Reported Earnings • May 02First quarter 2026 earnings released: EPS: kr1.82 (vs kr2.52 in 1Q 2025)First quarter 2026 results: EPS: kr1.82 (down from kr2.52 in 1Q 2025). Revenue: kr2.01b (down 1.5% from 1Q 2025). Net income: kr182.0m (down 28% from 1Q 2025). Profit margin: 9.1% (down from 12% in 1Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.
Upcoming Dividend • Apr 10Upcoming dividend of kr4.75 per shareEligible shareholders must have bought the stock before 17 April 2026. Payment date: 27 April 2026. Payout ratio and cash payout ratio are on the higher end at 76% and 84% respectively. Trailing yield: 2.7%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (3.9%).
Declared Dividend • Feb 06Dividend increased to kr4.75Dividend of kr4.75 is 12% higher than last year. Ex-date: 17th April 2026 Payment date: 27th April 2026 Dividend yield will be 2.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (76% earnings payout ratio) and cash flows (84% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 05Full year 2025 earnings released: EPS: kr6.22 (vs kr8.26 in FY 2024)Full year 2025 results: EPS: kr6.22 (down from kr8.26 in FY 2024). Revenue: kr7.71b (up 1.3% from FY 2024). Net income: kr620.0m (down 25% from FY 2024). Profit margin: 8.0% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Reported Earnings • Jul 19Second quarter 2026 earnings released: kr1.27 loss per share (vs kr2.56 profit in 2Q 2025)Second quarter 2026 results: kr1.27 loss per share (down from kr2.56 profit in 2Q 2025). Revenue: kr2.11b (up 3.4% from 2Q 2025). Net loss: kr127.0m (down 150% from profit in 2Q 2025). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 12% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
New Risk • May 02New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.2% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
Reported Earnings • May 02First quarter 2026 earnings released: EPS: kr1.82 (vs kr2.52 in 1Q 2025)First quarter 2026 results: EPS: kr1.82 (down from kr2.52 in 1Q 2025). Revenue: kr2.01b (down 1.5% from 1Q 2025). Net income: kr182.0m (down 28% from 1Q 2025). Profit margin: 9.1% (down from 12% in 1Q 2025). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 7.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year.
Upcoming Dividend • Apr 10Upcoming dividend of kr4.75 per shareEligible shareholders must have bought the stock before 17 April 2026. Payment date: 27 April 2026. Payout ratio and cash payout ratio are on the higher end at 76% and 84% respectively. Trailing yield: 2.7%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (3.9%).
Declared Dividend • Feb 06Dividend increased to kr4.75Dividend of kr4.75 is 12% higher than last year. Ex-date: 17th April 2026 Payment date: 27th April 2026 Dividend yield will be 2.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (76% earnings payout ratio) and cash flows (84% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 05Full year 2025 earnings released: EPS: kr6.22 (vs kr8.26 in FY 2024)Full year 2025 results: EPS: kr6.22 (down from kr8.26 in FY 2024). Revenue: kr7.71b (up 1.3% from FY 2024). Net income: kr620.0m (down 25% from FY 2024). Profit margin: 8.0% (down from 11% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 04Borregaard ASA Proposes Ordinary Dividend for 2025, Payable on 27 April 2026The Board of Directors of Borregaard ASA at a meeting on 3 February 2026 decided to propose an ordinary dividend for 2025 of NOK 4.75 per share to the Annual General Meeting. Dividend payment is estimated at NOK 474 million. The exact amount will depend on the number of treasury shares held at the date of the Annual General Meeting. No dividend will be paid on treasury shares held by the Borregaard Group. Provided that the traded shares are subject to ordinary settlement in the Norwegian Securities Register (VPS), shares acquired up to and including 16 April 2026 will carry the right to receive dividends, whereas shares that are acquired on and after 17 April 2026 will not carry the right to receive dividends. Subject to the decision of the Annual General Meeting, the dividend will be paid on 27 April 2026 to shareholders registered in the company’s shareholders’ register as evidenced in a transcript as of 20 April 2026. The share will be quoted ex dividend on 17 April 2026. The Annual General Meeting of Borregaard ASA will be held on Thursday 16 April 2026 at 1 p.m. (13:00 CEST) in Sarpsborg as a digital meeting.
Board Change • Dec 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director John Ulvan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Sep 27Borregaard Announces NOK 15 Million Award for Biomer Project to Develop Bio-Based Alternatives to PolycarboxylatesThe Norwegian Research Council has awarded NOK 15 million to support Borregaard’s innovation initiative, Biomer. The project aims to develop bio-based alternatives to polycarboxylates – fossil-based polymers commonly used in agriculture, industry, and household products. Polycarboxylates are known for their persistence in the environment and high carbon footprint. Through Biomer, Borregaard will develop new ways to turn Norwegian bioresources into greener polymers designed to replace these fossil-based materials. The project will leverage Borregaard’s advanced biorefinery in Sarpsborg and its expertise in wood chemistry to deliver sustainable solutions with significantly lower environmental impact.
お知らせ • Aug 25+ 5 more updatesBorregaard ASA to Report Q1, 2026 Results on Apr 29, 2026Borregaard ASA announced that they will report Q1, 2026 results on Apr 29, 2026
New Risk • Jul 17New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 41% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Dividend is not well covered by cash flows (91% cash payout ratio).
Reported Earnings • Jul 17Second quarter 2025 earnings released: EPS: kr2.56 (vs kr2.45 in 2Q 2024)Second quarter 2025 results: EPS: kr2.56 (up from kr2.45 in 2Q 2024). Revenue: kr2.05b (up 4.9% from 2Q 2024). Net income: kr255.0m (up 4.5% from 2Q 2024). Profit margin: 13% (in line with 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 5% per year.
Buy Or Sell Opportunity • Jul 16Now 23% undervaluedOver the last 90 days, the stock has risen 20% to kr197. The fair value is estimated to be kr255, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.8% over the last 3 years, while earnings per share has been flat.
お知らせ • Jun 21+ 1 more updateBorregaard ASA Announces Earnings Guidance for the Second Quarter of 2025 and the Full Year 2025Borregaard ASA announced earnings guidance for the second quarter and the full year 2025. For the second quarter, the sales volume is expected to be approximately 85,000 tonnes, which is seasonally higher than in the first quarter. The company expects a less favorable product mix as they normally have lower sales and lower share of specialties. Still, the sales will be driven by strong sales through agriculture also . For the full year 2025,the sales volume is expected to be approximately 330,000 tonnes, driven by strong sales through agriculture. This also implies a positive mix effect.
お知らせ • Jun 13Borregaard ASA Announces Change in Group Executive Management, Effective August 1, 2025Knut-Harald Bakke has been appointed EVP BioSolutions, effective 1 August 2025. He will also join the Group Executive Management on the same date. Bakke succeeds Tom Erik Foss-Jacobsen, who will assume the role of CEO on 1 August. Bakke currently serves as Director of Investor Relations and has previously held the position of Energy Director at Borregaard. Prior to joining the company in 2019, he held senior leadership roles at Norsk Hydro, where he was responsible for global energy market operations. He holds an MSc in Industrial Economics and Technology Management from the Norwegian University of Science and Technology (NTNU). Borregaard will initiate a process to appoint a new Director of Investor Relations. In the interim, CFO Per Bjarne Lyngstad will assume the responsibility from 1 August.
Recent Insider Transactions • Jun 02Independent Director recently bought kr376k worth of stockOn the 27th of May, John Ulvan bought around 2k shares on-market at roughly kr188 per share. This transaction amounted to 57% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr752k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • May 30Independent Director recently bought kr376k worth of stockOn the 27th of May, John Ulvan bought around 2k shares on-market at roughly kr188 per share. This transaction amounted to 57% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr752k more in shares than they have sold in the last 12 months.
Reported Earnings • May 02First quarter 2025 earnings released: EPS: kr2.52 (vs kr2.01 in 1Q 2024)First quarter 2025 results: EPS: kr2.52 (up from kr2.01 in 1Q 2024). Revenue: kr2.04b (up 3.1% from 1Q 2024). Net income: kr251.0m (up 26% from 1Q 2024). Profit margin: 12% (up from 10% in 1Q 2024). Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 1% per year.
Upcoming Dividend • Apr 04Upcoming dividend of kr4.25 per shareEligible shareholders must have bought the stock before 11 April 2025. Payment date: 23 April 2025. Payout ratio is a comfortable 51% but the company is paying out more than the cash it is generating. Trailing yield: 2.6%. Lower than top quartile of British dividend payers (6.2%). Lower than average of industry peers (4.7%).
Reported Earnings • Mar 23Full year 2024 earnings released: EPS: kr8.26 (vs kr8.73 in FY 2023)Full year 2024 results: EPS: kr8.26 (down from kr8.73 in FY 2023). Revenue: kr7.62b (up 6.8% from FY 2023). Net income: kr823.0m (down 5.4% from FY 2023). Profit margin: 11% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year.
Declared Dividend • Jan 31Dividend increased to kr4.25Dividend of kr4.25 is 13% higher than last year. Ex-date: 11th April 2025 Payment date: 23rd April 2025 Dividend yield will be 2.1%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (52% earnings payout ratio) but not covered by cash flows (119% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Jan 30Full year 2024 earnings released: EPS: kr8.25 (vs kr8.73 in FY 2023)Full year 2024 results: EPS: kr8.25 (down from kr8.73 in FY 2023). Revenue: kr7.62b (up 6.8% from FY 2023). Net income: kr823.0m (down 5.4% from FY 2023). Profit margin: 11% (down from 12% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year.
お知らせ • Jan 29Borregaard Asa Proposes Ordinary Dividend for 2024, Payable on 23 April 2025At a meeting on 30 January 2024, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary dividend for 2024 of NOK 4.25 per share. Ex-date: 11 April 2025. Record date: 14 April 2025. Payment date: 23 April 2025. Date of approval: 10 April 2025.
Reported Earnings • Nov 01Third quarter 2024 earnings released: EPS: kr2.51 (vs kr2.38 in 3Q 2023)Third quarter 2024 results: EPS: kr2.51 (up from kr2.38 in 3Q 2023). Revenue: kr1.95b (up 14% from 3Q 2023). Net income: kr250.0m (up 5.5% from 3Q 2023). Profit margin: 13% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
お知らせ • Sep 20Borregaard ASA, Annual General Meeting, Apr 10, 2025Borregaard ASA, Annual General Meeting, Apr 10, 2025.
お知らせ • Sep 19+ 3 more updatesBorregaard ASA to Report Q3, 2025 Results on Oct 22, 2025Borregaard ASA announced that they will report Q3, 2025 results on Oct 22, 2025
Reported Earnings • Jul 18Second quarter 2024 earnings released: EPS: kr2.45 (vs kr2.84 in 2Q 2023)Second quarter 2024 results: EPS: kr2.45 (down from kr2.84 in 2Q 2023). Revenue: kr1.95b (flat on 2Q 2023). Net income: kr244.0m (down 14% from 2Q 2023). Profit margin: 13% (down from 14% in 2Q 2023). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 6.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Board Change • May 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director John Ulvan was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: kr2.01 (vs kr2.32 in 1Q 2023)First quarter 2024 results: EPS: kr2.01 (down from kr2.32 in 1Q 2023). Revenue: kr1.98b (up 6.8% from 1Q 2023). Net income: kr200.0m (down 13% from 1Q 2023). Profit margin: 10% (down from 13% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Apr 05Upcoming dividend of kr3.75 per shareEligible shareholders must have bought the stock before 12 April 2024. Payment date: 22 April 2024. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (2.9%).
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: kr8.73 (vs kr8.95 in FY 2022)Full year 2023 results: EPS: kr8.73 (down from kr8.95 in FY 2022). Revenue: kr7.13b (up 3.6% from FY 2022). Net income: kr870.0m (down 2.5% from FY 2022). Profit margin: 12% (in line with FY 2022). Revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 3.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Feb 07Now 21% undervaluedOver the last 90 days, the stock has risen 9.3% to kr176. The fair value is estimated to be kr224, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 21%. For the next 3 years, revenue is forecast to grow by 3.1% per annum. Earnings are also forecast to grow by 9.2% per annum over the same time period.
Declared Dividend • Feb 02Dividend increased to kr3.75Dividend of kr3.75 is 15% higher than last year. Ex-date: 12th April 2024 Payment date: 22nd April 2024 Dividend yield will be 2.0%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (43% earnings payout ratio) and cash flows (42% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 30% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 01Full year 2023 earnings released: EPS: kr8.73 (vs kr8.95 in FY 2022)Full year 2023 results: EPS: kr8.73 (down from kr8.95 in FY 2022). Revenue: kr7.13b (up 3.6% from FY 2022). Net income: kr870.0m (down 2.5% from FY 2022). Profit margin: 12% (in line with FY 2022). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 4.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 31Borregaard ASA Proposes Cash Dividend for 2023, Payable on 22 April 2024At a meeting on 30 January 2024, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary dividend for 2023 of NOK 3.75 per share. Ex-date: 12 April 2024. Record date: 15 April 2024. Payment date: 22 April 2024. Date of approval: 11 April 2024.
お知らせ • Nov 29Borregaard ASA (OB:BRG) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved from April 18, 2023.Borregaard ASA (OB:BRG) commences share repurchases on November 20, 2023, under the program mandated by the shareholders in the Annual General Meeting held on April 18, 2023. As per the mandate, the company is authorized to repurchase up to a total nominal value of NOK 10 million, corresponding to 10% of the share capital. The shares will be repurchased at a price not more than NOK 400 per share and no less than NOK 1 per share. The company may repurchase and dispose of its own shares to fulfil its incentive schemes. The repurchases will be used for amortization. The plan will be valid up to the 2024 Annual General Meeting, but no later than June 30, 2024. On November 17, 2023, the company announced its intention of repurchasing 200,000 shares of its outstanding common stock. The repurchase of shares will be conducted in a period from November 20, 2023, up to and including December 20, 2023 at the latest.
Reported Earnings • Oct 25Third quarter 2023 earnings released: EPS: kr2.38 (vs kr2.40 in 3Q 2022)Third quarter 2023 results: EPS: kr2.38 (down from kr2.40 in 3Q 2022). Revenue: kr1.71b (down 2.2% from 3Q 2022). Net income: kr237.0m (flat on 3Q 2022). Profit margin: 14% (in line with 3Q 2022). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 6.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 25+ 5 more updatesBorregaard ASA, Annual General Meeting, Apr 11, 2024Borregaard ASA, Annual General Meeting, Apr 11, 2024, at 13:00 Central European Standard Time.
New Risk • Jul 19New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 43% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company.
Reported Earnings • Jul 19Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr1.96b (up 13% from 2Q 2022). Net income: kr283.0m (up 12% from 2Q 2022). Profit margin: 14% (in line with 2Q 2022). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 7.5% decline forecast for the Chemicals industry in the United Kingdom.
Buying Opportunity • Jun 12Now 20% undervaluedOver the last 90 days, the stock is up 7.5%. The fair value is estimated to be kr229, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 11% in 2 years. Earnings is forecast to grow by 6.5% in the next 2 years.
Buying Opportunity • May 26Now 20% undervaluedOver the last 90 days, the stock is up 3.4%. The fair value is estimated to be kr231, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 11% in 2 years. Earnings is forecast to grow by 6.5% in the next 2 years.
Reported Earnings • May 03First quarter 2023 earnings released: EPS: kr2.32 (vs kr2.18 in 1Q 2022)First quarter 2023 results: EPS: kr2.32 (up from kr2.18 in 1Q 2022). Revenue: kr1.85b (up 15% from 1Q 2022). Net income: kr231.0m (up 6.5% from 1Q 2022). Profit margin: 13% (in line with 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Apr 12Upcoming dividend of kr3.25 per share at 1.9% yieldEligible shareholders must have bought the stock before 19 April 2023. Payment date: 27 April 2023. Payout ratio is a comfortable 36% but the company is paying out more than the cash it is generating. Trailing yield: 1.9%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (2.4%).
Reported Earnings • Feb 05Full year 2022 earnings released: EPS: kr8.95 (vs kr6.95 in FY 2021)Full year 2022 results: EPS: kr8.95 (up from kr6.95 in FY 2021). Revenue: kr6.88b (up 19% from FY 2021). Net income: kr892.0m (up 29% from FY 2021). Profit margin: 13% (up from 12% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 1.6% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to kr179, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 96% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at kr78.03 per share.
お知らせ • Feb 02Borregaard ASA Proposes Ordinary Dividend for 2022, Payable on 27 April 2023At a meeting on 1 February 2023, the Board of Directors of Borregaard ASA decided to propose to the Annual General Meeting an ordinary dividend for 2022 of NOK 3.25 per share. Ex-date: 19 April 2023; Record date: 20 April 2023; Payment date: 27 April 2023; Date of approval: 18 April 2023.
Recent Insider Transactions • Dec 11Independent Chairman recently bought kr95k worth of stockOn the 9th of December, Helge Aasen bought around 600 shares on-market at roughly kr159 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr217k. This was Helge's only on-market trade for the last 12 months.
Recent Insider Transactions • Dec 11Independent Chairman recently bought kr95k worth of stockOn the 9th of December, Helge Aasen bought around 600 shares on-market at roughly kr159 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr217k. This was Helge's only on-market trade for the last 12 months.
Recent Insider Transactions • Nov 03Director recently bought kr217k worth of stockOn the 1st of November, John Ulvan bought around 2k shares on-market at roughly kr145 per share. This transaction amounted to 75% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.5m more in shares than they have sold in the last 12 months.
Buying Opportunity • Nov 02Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 20%. The fair value is estimated to be kr179, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 29%. For the next 3 years, revenue is forecast to grow by 1.4% per annum. Earnings is forecast to decline by 1.6% per annum over the same time period.
Reported Earnings • Oct 21Third quarter 2022 earnings released: EPS: kr2.40 (vs kr2.12 in 3Q 2021)Third quarter 2022 results: EPS: kr2.40 (up from kr2.12 in 3Q 2021). Revenue: kr1.75b (up 23% from 3Q 2021). Net income: kr239.0m (up 13% from 3Q 2021). Profit margin: 14% (down from 15% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.4% p.a. on average during the next 3 years, compared to a 8.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 27+ 4 more updatesBorregaard ASA to Report Q4, 2022 Results on Feb 02, 2023Borregaard ASA announced that they will report Q4, 2022 results at 7:00 AM, Central European Standard Time on Feb 02, 2023
Reported Earnings • Jul 16Second quarter 2022 earnings released: EPS: kr2.52 (vs kr2.34 in 2Q 2021)Second quarter 2022 results: EPS: kr2.52 (up from kr2.34 in 2Q 2021). Revenue: kr1.74b (up 15% from 2Q 2021). Net income: kr252.0m (up 8.2% from 2Q 2021). Profit margin: 14% (down from 15% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 12% compared to a 16% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • May 14Insider recently bought kr709k worth of stockOn the 12th of May, Gisle Johansen bought around 11k shares on-market at roughly kr65.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr2.3m more in shares than they have sold in the last 12 months.
Reported Earnings • May 03First quarter 2022 earnings released: EPS: kr2.18 (vs kr1.46 in 1Q 2021)First quarter 2022 results: EPS: kr2.18 (up from kr1.46 in 1Q 2021). Revenue: kr1.62b (up 14% from 1Q 2021). Net income: kr217.0m (up 49% from 1Q 2021). Profit margin: 13% (up from 10% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to stay flat compared to a 16% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 26% per year.
Upcoming Dividend • Apr 01Upcoming dividend of kr5.00 per shareEligible shareholders must have bought the stock before 08 April 2022. Payment date: 21 April 2022. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (4.7%). Lower than average of industry peers (2.6%).
Reported Earnings • Mar 19Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: kr5.81b (up 9.0% from FY 2020). Net income: kr692.0m (up 59% from FY 2020). Profit margin: 12% (up from 8.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 3.1% compared to a 11% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Feb 04Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: kr6.95 (up from kr4.37 in FY 2020). Revenue: kr5.81b (up 9.0% from FY 2020). Net income: kr692.0m (up 59% from FY 2020). Profit margin: 12% (up from 8.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 8.5% compared to a 3.3% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Dec 07Insider recently bought kr710k worth of stockOn the 6th of December, Kristin Misund bought around 10k shares on-market at roughly kr70.95 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr3.0m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Nov 27General Counsel recently sold kr268k worth of stockOn the 25th of November, Rolf Heggen sold around 1k shares on-market at roughly kr223 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr2.3m more than they sold in the last 12 months.
Recent Insider Transactions • Oct 28Independent Director recently bought kr424k worth of stockOn the 27th of October, Tove Andersen bought around 2k shares on-market at roughly kr212 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr1.4m. Insiders have collectively bought kr2.5m more in shares than they have sold in the last 12 months.
Reported Earnings • Oct 22Third quarter 2021 earnings released: EPS kr2.12 (vs kr1.12 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr1.43b (up 13% from 3Q 2020). Net income: kr211.0m (up 88% from 3Q 2020). Profit margin: 15% (up from 8.9% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Jul 30General Counsel recently bought kr1.4m worth of stockOn the 29th of July, Rolf Heggen bought around 15k shares on-market at roughly kr91.56 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr461k more in shares than they have sold in the last 12 months.
Reported Earnings • Jul 17Second quarter 2021 earnings released: EPS kr2.34The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr1.51b (up 11% from 2Q 2020). Net income: kr233.0m (up 131% from 2Q 2020). Profit margin: 15% (up from 7.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 29First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr1.42b (up 3.4% from 1Q 2020). Net income: kr146.0m (up 43% from 1Q 2020). Profit margin: 10% (up from 7.4% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
Executive Departure • Apr 20Independent Chairman Jan Oksum has left the companyOn the 14th of April, Jan Oksum's tenure in the role of Independent Chairman ended. We don't have any record of a personal shareholding under Jan's name. Jan is the only executive to leave the company over the last 12 months.
Upcoming Dividend • Apr 08Upcoming dividend of kr2.50 per shareEligible shareholders must have bought the stock before 15 April 2021. Payment date: 23 April 2021. Trailing yield: 1.3%. Lower than top quartile of British dividend payers (4.3%). Lower than average of industry peers (1.7%).
Reported Earnings • Mar 26Full year 2020 earnings released: EPS kr4.37 (vs kr4.18 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr5.33b (up 5.2% from FY 2019). Net income: kr436.0m (up 4.6% from FY 2019). Profit margin: 8.2% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.
Recent Insider Transactions • Mar 20Insider recently bought kr1.4m worth of stockOn the 18th of March, Gisle Johansen bought around 15k shares on-market at roughly kr94.06 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr205k more in shares than they bought in the last 12 months.
Is New 90 Day High Low • Feb 20New 90-day high: kr168The company is up 27% from its price of kr132 on 20 November 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr169 per share.
Reported Earnings • Feb 05Full year 2020 earnings released: EPS kr4.36 (vs kr4.17 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr5.33b (up 5.2% from FY 2019). Net income: kr436.0m (up 4.6% from FY 2019). Profit margin: 8.2% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 05Revenue beats expectationsRevenue exceeded analyst estimates by 2.2%. Over the next year, revenue is expected to shrink by 1.2% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom.
Is New 90 Day High Low • Feb 05New 90-day high: kr167The company is up 22% from its price of kr137 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr162 per share.
Is New 90 Day High Low • Jan 05New 90-day high: kr145The company is up 2.0% from its price of kr142 on 07 October 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr165 per share.
Analyst Estimate Surprise Post Earnings • Oct 22Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 0.3% at kr1.26b. Revenue is forecast to grow 2.3% over the next year, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.
Reported Earnings • Oct 22Third quarter earnings releasedOver the last 12 months the company has reported total profits of kr353.0m, down 23% from the prior year. Total revenue was kr5.22b over the last 12 months, up 3.5% from the prior year.
Recent Insider Transactions • Sep 18Board Observer recently sold kr67k worth of stockOn the 15th of September, Bente Klausen sold around 500 shares on-market at roughly kr133 per share. In the last 3 months, there was an even bigger sale from another insider worth kr1.3m. Insiders have been net sellers, collectively disposing of kr919k more than they bought in the last 12 months.
